Trials / Completed
CompletedNCT05098262
Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State
An Open Label, Randomized, Single Dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of DA-5210 10/500mg in Healthy Subjects at Fasting State
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy subjects at Fasting State
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DA-5210 10/500mg | single dose administration (one tablet once a day) |
| DRUG | DA-5210-R 10/500mg | single dose administration (one tablet once a day) |
Timeline
- Start date
- 2021-10-31
- Primary completion
- 2022-01-03
- Completion
- 2022-01-03
- First posted
- 2021-10-28
- Last updated
- 2022-06-06
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05098262. Inclusion in this directory is not an endorsement.